Evidence map›Paper›PMID 40670989›Full record

ArticleBMC complementary medicine and therapies2025

Prunus amygdalus var. amara seed extract enhances the antileishmanial activity of miltefosine.

Sajjadul Kadir Akand, Areeba Rahman, Rahat Ali, Mohammad Husain, Mohd Danish, Mohammad Rashid Khan, Nemat Ali, Mohd Faiz Akram, Abdur Rub

Abstract read
In one paragraph

Article in BMC complementary medicine and therapies, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Sajjadul Kadir Akand *Department of Biotechnology, Jamia Millia Islamia (A Central University), New Delhi, 110025, India.
Areeba Rahman *Department of Biotechnology, Jamia Millia Islamia (A Central University), New Delhi, 110025, India.
Rahat AliDepartment of Dermatology, University of Alabama, 1720 2nd Ave South, Birmingham, AL35294, USA.
Mohammad HusainDepartment of Biotechnology, Jamia Millia Islamia (A Central University), New Delhi, 110025, India.
Mohd DanishDepartment of Biotechnology, Jamia Millia Islamia (A Central University), New Delhi, 110025, India.
Mohammad Rashid KhanDepartment of Pharmacology and Toxicology, College of Pharmacy, King Saud University, P.O. Box 2457, Riyadh, 11451, Saudi Arabia.
Nemat AliDepartment of Pharmacology and Toxicology, College of Pharmacy, King Saud University, P.O. Box 2457, Riyadh, 11451, Saudi Arabia.
Mohd Faiz AkramFaculty of Dentistry, Department of Pharmacology, Jamia Millia Islamia (A Central University), New Delhi, India, 110025.
Abdur RubDepartment of Biotechnology, Jamia Millia Islamia (A Central University), New Delhi, 110025, India. arub@jmi.ac.in.

Funding

Indian Council of Medical Research (6/9-7(317)2023-ECD-II)Ministry of AYUSH, Government of India Z.28015/252/2016
6 · The paper itself

Abstract

backgroundLeishmaniasis, an infectious disease transmitted via sand flies is caused by the protozoan parasite of Leishmania spp. The treatment of this disease is quite challenging due to the high cost, resistance, and toxicity of conventional drugs. Various research studies have demonstrated that plant based drug possess least toxicity, anti-inflammatory and anti-oxidant properties. Here, evaluation of anti-leishmanial activity of methanolic Prunus amygdalus var. amara seed extract was conducted and found that it inhibited L. donovani proliferation and cause apoptosis. Moreover, its combinations with miltefosine enhanced antileishmanial effects. GC-MS analysis confirmed the presence of various phytochemicals in the extract that contributed pharmacological efficacy. These findings highlighted the potential of herbal products as a valuable source of new treatments for leishmaniasis.

methodsThe antileishmanial effect was determined by promastigote and amastigote assays. Parasite load was evaluated by staining L. donovani-infected macrophages with modified Giemsa stain. Cytotoxicity of seed extract was estimated by MTT (3-(4, 5- dimethylthiazol-2-yl)-2, 5-diphenyl tetrazolium bromide) assay. In addition, Pro-apoptotic events were inferred using RT-PCR and qRT-PCR. Further characterization of phytoconstituents was evaluated by gas chromatography and mass spectrometry.

resultsThe extract promoted a dose-dependent reduction in growth of promastigotes (IC50 = 43.12 ± 3.03 μg/ml) and amastigotes (IC50 = 49.65 ± 3.34 μg/ml). Further, extract in combination with miltefosine showed enhanced antileishmanial activity against both forms of the L. donovani, promastigotes (IC50 = 4.547 ± 1.2 μg/ml) as well as amastigotes (IC50 = 19.54 ± 2.4 μg/ml). Early-stage apoptotic events were also observed in promastigote forms by determining the increased expression of LdMetacaspase and PARP1. The cytotoxic potential on THP-1 differentiated macrophages was assessed and indicated insignificant cytotoxicity of different doses of the extract (CC50 = 799.19 ± 134.59 μg/ml) and in combination with miltefosine (CC50 = 384.16 ± 177.47 μg/ml). Furthermore, the presence of phytocompounds like chaulmoogric acid and hydnocarpic acid was described, for the first time, in Prunus amygdalus var. amara seed extract.

conclusionThe findings indicated that EPA plays a significant role in combating leishmaniasis and holds promise as a potential treatment for this disease. Moreover, when combined with miltefosine, EPA demonstrated increased effectiveness against leishmaniasis. Therefore, the combination of EPA and miltefosine presents a more promising outlook as a potential therapy for leishmaniasis.

Indexed as

Antiprotozoal AgentsLeishmania donovaniPhosphorylcholinePlant ExtractsAnimalsApoptosisHumansMiceSeedsAntiprotozoal AgentsmiltefosinePhosphorylcholinePlant ExtractsApoptosisIC50LeishmaniaLeishmaniasisMiltefosinePrunus amygdalus var. amara seed

Identifiers

PMID40670989
PMCPMC12269125

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.